# Panobinostat

Source: https://onco.cc/drugs/panobinostat/  
OnCo record `panobinostat` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

An HDAC inhibitor for relapsed myeloma approved in 2015 and withdrawn in 2021 after its confirmatory trial was never completed.

## Summary

Panobinostat is a pan-HDAC inhibitor that blocks class I, II and IV histone deacetylases including HDAC6. Inhibiting HDAC6 disrupts aggresome-mediated disposal of misfolded proteins, which synergises with proteasome inhibition in myeloma. PANORAMA-1 showed median progression-free survival of 12 versus 8.1 months when panobinostat was added to bortezomib-dexamethasone, at the cost of severe diarrhoea and cardiac events. The FDA granted accelerated approval in 2015 restricted to patients after at least two regimens including bortezomib and an immunomodulatory drug, and the EU approved it the same year. The confirmatory trial was never completed, and Secura Bio withdrew the US approval in 2021. Panobinostat showed that HDAC inhibition adds real activity in myeloma, but its toxicity meant the trade-off never earned a permanent place.

## Fields

- Kind: Treatment
- Status: withdrawn
- Last checked: 2026-09-08
- Tags: gap-fill
- Brand: Farydak
- Modality: Pan-HDAC inhibitor
- Mechanism: Inhibits class I, II and IV HDACs including HDAC6, disrupting aggresome-mediated protein disposal and synergising with proteasome inhibition in myeloma.
- Approvals: US 2015: Multiple myeloma after ≥2 regimens including bortezomib and an IMiD; EU 2015: Relapsed/refractory multiple myeloma

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/Panobinostat
- Wikipedia: https://en.wikipedia.org/wiki/Panobinostat

## Connected records

- cancers: [Multiple myeloma](https://onco.cc/cancers/multiple-myeloma/)
- technologies: [Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET)](https://onco.cc/technologies/epigenetic-drugs/)
- companies: [Novartis](https://onco.cc/companies/novartis/), [SecuraBio](https://onco.cc/companies/securabio/)
- trials: [Efficacy and Safety of Panobinostat (LBH589) in Patients With Refractory de Novo or Secondary Acute Myelogenous Leukemia (AML)](https://onco.cc/trials/nct00880269/), [Panobinostat, Gemcitabine Hydrochloride, Busulfan, and Melphalan Before Stem Cell Transplant in Treating Patients With Refractory or Relapsed Multiple Myeloma](https://onco.cc/trials/nct02506959/), [Phase II Study of Oral Panobinostat in Adult Participants With Relapsed/Refractory Classical Hodgkin's Lymphoma](https://onco.cc/trials/nct00742027/), [Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal Cancer](https://onco.cc/trials/nct05725200/)
- roadmaps: [Epigenetic therapy roadmap: loosening silenced genes → mutation-specific enzymes → editing the epigenome](https://onco.cc/roadmaps/epigenetics-roadmap/)

---
JSON: https://onco.cc/api/v1/entities/panobinostat.json